15-Site Trial to Compare Telehealth Cognitive Behavior

CINCINNATI, July 26, 2022 /PRNewswire/ — Researchers at Cincinnati Children’s have been approved for a $12.9 million funding award by the Patient-Centered Outcomes Research Institute (PCORI) to lead a multi-center study to compare two methods for helping adolescents manage their migraine pain.

The project, to be led by Scott Powers,

Read More

6 People Living With Migraine Share How They Prioritize

An estimated 39 million people in the U.S.—and roughly 10% of people worldwide—live with migraine; yet it’s an often misunderstood diagnosis.1 Migraine isn’t just “a bad headache” you can power through—it’s a complex neurological condition that can cause severe, throbbing head pain, plus other potentially debilitating symptoms like dizziness, blurred vision, severe sensitivity to light and sound, and nausea

Read More

Long COVID symptoms may include hair loss, ejaculation

Share on Pinterest
The symptoms of long COVID can vary from individual to individual. 10’000 Hours/Getty Images
  • Researchers analyzed primary care data from the United Kingdom to identify symptoms and risk factors for long COVID.
  • They found 62 symptoms of long COVID, including hair loss, and reduced libido, as well as several risk factors such as smoking or being socially
Read More

Bengaluru neurologists see rise in people reporting

Bengaluru-based neurologists said they are noticing a spike in complications like Guillain-Barre syndrome, Bell’s palsy, insomnia apart from behavioural and cognitive issues

Bengaluru-based neurologists said they are noticing a spike in complications like Guillain-Barre syndrome, Bell’s palsy, insomnia apart from behavioural and cognitive issues

There has been a rise in people reporting post-COVID-19 brain disorders. City-based neurologists said they are

Read More

Euro Roundup: EMA drug shortage group backs continued COVID

Roundups

| 14 July 2022 | By Nick Paul Taylor 


2741


The regulatory flexibilities offered to ease the impact of COVID-19 should be continued for now, according to the members of the European Medicines Agency’s (EMA) Medicines Shortages Steering Group (MSSG). The group, formed earlier this year to plan for future crisis preparedness, met for the fourth time on 7

Read More

AbbVie Submits Marketing Authorization Application to EMA

AbbVie (NYSE: ABBV) today announced it has submitted a marketing authorization application (MAA) to the European Medicines Agency (EMA) for atogepant for the prophylaxis of migraine in adult patients who have at least four migraine days per month. The application is supported by the pivotal Phase 3 ADVANCE and PROGRESS studies evaluating the safety, efficacy, and tolerability of atogepant in

Read More